We are live on ! Find out more
ALNY icon

Alnylam Pharmaceuticals
ALNY

821 hedge funds and large institutions have $59.2B invested in Alnylam Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 224 funds opening new positions, 282 increasing their positions, 223 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

357% more first-time investments, than exits

New positions opened: 224 | Existing positions closed: 49

44% more funds holding in top 10

Funds holding in top 10: 9 → 13 (+4)

37% more capital invested

Capital invested by funds: $43.1B → $59.2B (+$16.1B)

26% more repeat investments, than reductions

Existing positions increased: 282 | Existing positions reduced: 223

26% more funds holding

Funds holding: 653 → 821 (+168)

2.24% less ownership

Funds ownership: 101.33% → 99.09% (-2.2%)

13% less call options, than puts

Call options by funds: $562M | Put options by funds: $649M

Holders
821
Holders Change
+168
Holders Change %
+25.73%
% of All Funds
10.77%
Holding in Top 10
13
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+44.44%
% of All Funds
0.17%
New
224
Increased
282
Reduced
223
Closed
49
Calls
$562M
Puts
$649M
Net Calls
-$86.5M
Net Calls Change
-$71M

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$1.01B
2
Arrowstreet Capital
Arrowstreet Capital
Massachusetts
+$483M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$391M
4
Jane Street
Jane Street
New York
+$381M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$330M

Top Sellers

Rank Fund Capital Flow
1
RP
Regeneron Pharmaceuticals
New York
-$1.24B
2
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
-$858M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$548M
4
Winslow Capital Management
Winslow Capital Management
Minnesota
-$479M
5
Dodge & Cox
Dodge & Cox
California
-$357M
Name Holding Trade Value Shares
Change 		Change in
Stake
ZBNA
776
Zions Bancorporation, National Association
Utah
$4.1K -$259K -637 -99%
TIM
777
Tortoise Investment Management
New York
$4.1K +$1.22K +3 +50%
TFA
778
Toth Financial Advisory
Virginia
$4.1K +$1.63K +4 +80%
WWA
779
Wealth Watch Advisors
Colorado
$4.1K +$3.67K +9 New
PCM
780
Penserra Capital Management
California
$4K -$1.22K -3 -25%
CCM
781
Cloud Capital Management
Washington
$4K +$4.07K +10 New
WAM
782
WFA Asset Management
Wisconsin
$3.85K – – –
WTA
783
Washington Trust Advisors
Massachusetts
$3.83K -$70.9K -174 -96%
CIR
784
Clear Investment Research
Georgia
$3.65K – – –
FWM
785
FSA Wealth Management
Massachusetts
$3.65K – – –
HWP
786
Highline Wealth Partners
California
$3.65K +$407 +1 +14%
DPW
787
DiNuzzo Private Wealth
Pennsylvania
$3.57K -$1.63K -4 -33%
FRA
788
Front Row Advisors
California
$3.19K -$814 -2 -22%
CHC
789
City Holding Co
West Virginia
$3.19K +$2.85K +7 New
WW
790
Winnow Wealth
Texas
$3.19K +$2.85K +7 New
BHWM
791
Bay Harbor Wealth Management
Maryland
$2.74K – – –
MA
792
Montag & Associates
Georgia
$2.73K – – –
CIAS
793
CBIZ Investment Advisory Services
Ohio
$2.28K – – –
PWA
794
Principia Wealth Advisory
Texas
$2.28K – – –
ADL
795
Asset Dedication LLC
California
$2.28K +$2.04K +5 New
RWS
796
Retirement Wealth Solutions
Wisconsin
$2.28K +$2.04K +5 New
ACA
797
American Capital Advisory
Idaho
$1.82K – – –
BHWM
798
Beaird Harris Wealth Management
Texas
$1.82K +$407 +1 +33%
GWS
799
Greykasell Wealth Strategies
California
$1.82K +$1.63K +4 New
RS
800
Rakuten Securities
Japan
$1.82K +$1.63K +4 New
30 31
32
33 34

ALNY Hedge Fund Activity: Q3 2025 in Review

821 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q3 2025, worth a combined $59.2B — up 37% from $43.1B a quarter earlier.

Buyers outnumbered sellers: 224 funds opened new ALNY positions and 49 closed out — a net gain of 175 holders — while 282 added to existing stakes and 223 trimmed.

The largest buyer was JP Morgan Chase, adding an estimated $1.01B. The largest seller was Regeneron Pharmaceuticals, cutting an estimated $1.24B.

  • 821 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q3 2025, up from 653 in Q2 2025.
  • Funds reported $59.2B of Alnylam Pharmaceuticals stock for Q3 2025, up 37% quarter-over-quarter.
  • 224 funds opened new Alnylam Pharmaceuticals positions in Q3 2025 and 49 closed out, a net change of +175 holders.
  • The largest Alnylam Pharmaceuticals buyer in Q3 2025 was JP Morgan Chase, an estimated $1.01B added.
  • The largest Alnylam Pharmaceuticals seller in Q3 2025 was Regeneron Pharmaceuticals, an estimated $1.24B sold.

Based on aggregated 13F filings for Q3 2025.